MiNK Therapeutics宣布首例患者入组Agent-797治疗急性肺损伤与危重疾病的随机二期试验

美股速递
May 28

MiNK Therapeutics宣布,其候选药物Agent-797在针对急性肺损伤及危重疾病的随机二期临床试验中,已完成首例患者给药。这项试验旨在评估该药物的安全性与有效性,标志着其在相关治疗领域临床开发的重要进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10